BLTE · Belite Bio
AI read · Good for BLTE
The AI's read
A higher target and continued favorable rating show Mizuho sees more value in Belite Bio's shares. But this is an analyst's view, not a report of changed sales, costs, or trial results.
Mizuho raised its price target for Belite Bio to $230 from $221 after the company’s third-quarter earnings report.
Good for BLTE
Mizuho raised its Belite Bio target from $221 to $230 and kept its favorable rating. This supports a positive read for BLTE, though the story reports no new company results.
Get alerts for BLTE
Follow Belite Bio (BLTE) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for BLTEFree on the App Store and Google Play, or on the web.